UNSPSC 51171951: Niperotidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C20H26N4O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12JBD7U72K, chemically known as 1,1-ethenediamine, n-(1,3-benzodioxol-5-ylmethyl)-n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-2-nitro- but generally known as niperotidine, which bears US NIH Compound Identifier 3033952. European Medicines Agency schedules Niperotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09301MIG.

UNSPSC 51171951 Niperotidine is a Commodity code that reflects pharmaceutical procurement activity across state and local jurisdictions, though recent opportunities show limited direct alignment with this specific pharmaceutical substance. The code encompasses pharmaceutical sourcing for healthcare delivery, correctional health programs, and multi-state cooperative purchasing arrangements. State and local buyers under this code include county correction and community supervision departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local government facilities. The scope of actual procurement activity spans generic multi-source pharmaceuticals, over-the-counter products distributed through authorized pharmaceutical wholesalers, and specialized testing and screening services that may require pharmaceutical reagents or ancillary pharmaceutical support.

Recent activity shows niperotidine as a low-volume or specialized pharmaceutical with minimal direct solicitation. The most concrete recent opportunity is the Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026), which involves immunoassay screening and confirmation testing that may reference controlled substances in screening panels but does not explicitly name niperotidine procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, representing a broader generic pharmaceutical market. The Texas Health and Human Services Commission issued RFI HHS0017013 (due April 3, 2026) to explore direct-to-manufacturer prescription programs, indicating state-level interest in pharmaceutical sourcing optimization. Activity concentrates in Texas and Minnesota, with secondary participation through multi-state cooperative vehicles. The code shows limited recent procurement volume targeting niperotidine specifically.